Margarida Esteves

Margarida Esteves

Auto-generated profile, based on publicly available information

Margarida Esteves

INL ‐ International Iberian Nanotechnology Laboratory Avenida Mestre José Veiga, s/n Braga 4715‐330 Portugal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Advanced Science
Verified
Journal Article
Open access
ACAdriana Carneiro
Adriana Carneiro
MPMarta Aranda Palomer
Marta Aranda Palomer
MEMargarida Esteves
Margarida Esteves
CRCarolina Rodrigues
Carolina Rodrigues
JFJosé Maria Fernandes
José Maria Fernandes
Miguel XavierMiguel Xavier
Miguel Xavier
Cancer remains one of the leading causes of mortality worldwide, accounting for ≈10 million deaths annually. Critically, it is metastasis and not the primary tumour that causes most of these deaths. Understanding the mechanisms behind cancer dissemination and therapy resistance is thus a pressing challenge. Traditional bulk tissue analyses have failed to capture the full spectrum of intra‐tumour heterogeneity and the dynamic interactions within the tumour microenvironment. Studying cancer at the single‐cell level allows unravelling the roles of rare subpopulations, cell–cell interactions, and spatial dynamics that govern tumour evolution, metastasis, and immune evasion. This review explores how recent advances in microfluidic technologies are transforming ability to model and study cancer at the single‐cell level. Cutting‐edge platforms are highlighted, including droplet microfluidics, single cell‐derived spheroids, and tumour‐chips, that enable physiologically relevant 3D cancer models. By integrating immune components, biosensing, and patient‐derived materials, these platforms hold promise for advancing drug screening, immunotherapy assessment, and personalised medicine. It is concluded by identifying key challenges and priorities for future work, which should focus on increasing model complexity, reproducibility, and integration of spatiotemporal multiomics to better dissect tumour heterogeneity and accelerate clinical translation.

1 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MEMargarida Esteves
Margarida Esteves
FOFrancisca Oliveira
Francisca Oliveira
ATAlexandra Teixeira
Alexandra Teixeira
AIArantxa Ibáñez
Arantxa Ibáñez
AGAndrea Garcia-Lizarribar
Andrea Garcia-Lizarribar
SASara Abalde-Cela
Sara Abalde-Cela
Breast cancer remains a leading cause of cancer-related mortality, with disease progression and metastasis posing significant challenges in treatment. Three-dimensional (3D) cancer models have emerged as valuable tools for studying cancer cell biology in a physiologically relevant microenvironment. Studying the tumour heterogeneity and metabolic adaptations at the single-cell level can be crucial to identify factors driving metastatic progression. Here, we present a novel approach to generate single cell-derived breast cancer spheroids using cell lines (MCF-7 and MCF-10A) within a decellularised adipose tissue extracellular matrix (adECM). Spheroid culture conditions were optimised with integrated plasmonic nanosensors (gold nanostars - GNSs), to enable real-time surface-enhanced Raman scattering (SERS)-based measurements. Our results demonstrated that spheroid growth kinetics and viability in adECM were comparable to commonly used animal-derived matrices, validating its use as a reproducible ECM hydrogel. We further show that the concentration of plasmonic nanosensors used was compatible with cell culture and enabled SERS detection of a model reporter, paving the way for label-free, non-destructive analysis of cancer cell metabolism. This platform offers a promising approach to study cancer progression, including metabolic adaptations, with potential applications in biomarker discovery and preclinical research.